Questions?

What stage is this research?

Ifetroban research is at the clinical stage, meaning it has advanced to clinical trials involving people. Ifetroban has been studied in 27 clinical trials and has been dosed in nearly 1,400 people including healthy volunteers. There are two ongoing clinical trials evaluating ifetroban in other rare diseases. Animal studies mimicking Duchenne demonstrated ifetroban prevents heart muscle disease and prolongs survival. Ifetroban was also shown to be cardioprotective in animal models of non-DMD heart disease. Recruitment started in 2020.

Is the study completed?

The Fight DMD Trial closed to enrollment in January 2025. All active patients have completed the 12-month treatment period. The open-label extension is still active with active participants receiving ifetroban.

Where can I find the results of the study?

Please see our press release in the “Press” section of the website, which outlines the first set of results that were presented at the MDA 2025 meeting.

What is the goal or purpose of this study?

The goal of the FIGHT DMD trial is to slow or prevent the heart disease associated with Duchenne muscular dystrophy.
 

Who is funding this study?

This study is funded by the FDA Orphan Product Development (OPD) program and Cumberland Pharmaceuticals. The FIGHT DMD trial is the first DMD trial awarded FDA OPD funding to study an orphan product for DMD. Cumberland Pharmaceuticals is the grant recipient and responsible for the Ifetroban DMD clinical program.